Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
February 7th 2022Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Read More
Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL
November 12th 2021Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More